 GlycoMimetics, Inc. Nasdaq: GLYC today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occlusive crisis VOC shows that patients treated with rivipansel within approximately 26 hours of the onset of pain in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placebo. This analysis and new biomarker data will be presented at the September meeting of the Foundation for Sickle Cell Disease Research FSCDR. In addition to the rivipansel poster, an abstract containing data on GlycoMimetics more selective and highly potent E-selectin antagonist, GMI-1687, has been accepted for an oral presentation. The GMI-1687 abstract includes data from a preclinical model showing the drug candidates potential as a subcutaneously administered treatment for VOC. FSCDR posted the abstracts online today for the meeting now scheduled for September 23-25, 2020, in Ft. Lauderdale, FL. 